Amgen

Management’s recent priorities: integrate Horizon (closed October 2023 under FTC consent order), defend core franchises, invest in late‑stage programs, and pay down acquisition debt. The team raised the dividend to 2.38 dollars per quarter in 2025 and paused repurchases while reducing debt.

The Horizon deal adds durable rare‑disease cash flows but increases regulatory oversight on contracting. An Otezla intangible impairment in Q1 2025 reflects discipline in updating asset values. Overall, capital deployment is rational and shareholder‑aware, with a prudent near‑term focus on deleveraging.